it has been found possible to reduce the number of radiation fields in combined modality therapy : for patients with stage ia-iia lymphocyte predominant or nodular sclerosing hodgkin 's disease it was sufficient only to treat clinically involved sites .
C0024264
lymphocyte
C0152268
nodular sclerosing hodgkin 's disease